Effectiveness of ivermectin in rats with haloperidol induced tardive dyskinesia.
Article Sidebar
Main Article Content
Introduction: Extrapiramidal symptoms and tardive dyskinesia are common problems associated with antypsychotic therapy. Basic and clinical research is warranted due to the lack of effective therapies aimed to the prevention and treatment of antipsychotic side effects.
Objective: To evaluate the effect of ivermectin in rats with haloperidol induced tardive dyskinesia.
Methods: The effect of ivermectin on motor behavior and abnormal movements was tested in Sprague-Dawley rats treated with a single dose of haloperidol. In addition, a chronic animal model known as VCM (vacuous chewing movements) was implemented with the objective to evaluate the effect of ivermectin on the frequency of orofacial movements during a period of six months.
Results: Ivermectin does not prevent the motor behavior and frequency of abnormal movements induced by haloperidol in the acute model. Orofacial movements were not reduced with ivermectin in the chronic model. In addition, ivermectin was not associated with changes in motor behavior and abnormal movements in the acute and chronic model.
Conclusions: Ivermectin is not a good candidate for the treatment of tardive dyskinesia and the results of this study do not support the GABAergic hypothesis in the physiopathology of tardive dyskinesia. Additionally, ivermectin does not induce abnormal movements.
Objective: To evaluate the effect of ivermectin in rats with haloperidol induced tardive dyskinesia.
Methods: The effect of ivermectin on motor behavior and abnormal movements was tested in Sprague-Dawley rats treated with a single dose of haloperidol. In addition, a chronic animal model known as VCM (vacuous chewing movements) was implemented with the objective to evaluate the effect of ivermectin on the frequency of orofacial movements during a period of six months.
Results: Ivermectin does not prevent the motor behavior and frequency of abnormal movements induced by haloperidol in the acute model. Orofacial movements were not reduced with ivermectin in the chronic model. In addition, ivermectin was not associated with changes in motor behavior and abnormal movements in the acute and chronic model.
Conclusions: Ivermectin is not a good candidate for the treatment of tardive dyskinesia and the results of this study do not support the GABAergic hypothesis in the physiopathology of tardive dyskinesia. Additionally, ivermectin does not induce abnormal movements.
- Haloperidol
- Ivermectin
- Dyskinesia drug induced
- Antipsychotic agents
Palacios, M., & Pimienta, H. (2008). Effectiveness of ivermectin in rats with haloperidol induced tardive dyskinesia. Colombia Medica, 39(3.Supl.3), 71–77. https://doi.org/10.25100/cm.v39i3Supl3.608
Downloads
Download data is not yet available.
- Mauricio Palacios, EDITORIAL AVOIDABLE MORTALITY OF SCIENTIFIC MANUSCRIPTS , Colombia Medica: Vol. 41 No. 2 (2010)
- Mauricio Palacios, Jorge Hernán Ramírez, Editor’s duty on cases of scientific misconduct. , Colombia Medica: Vol. 39 No. 1 (2008)
- Hernán Pimienta, Martha Isabel Escobar B., Arquitectura dendrítica de la corteza somatosensorial. Estudio basado en la utilización de anticuerpos monoclonales (anti-MAP2) , Colombia Medica: Vol. 16 No. 3,4 (1985)
- Hernán Pimienta, Editorial. , Colombia Medica: Vol. 39 No. 3.Supl.3 (2008): Neurociencias
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use